Search

Your search keyword '"Frumovitz, Michael"' showing total 327 results

Search Constraints

Start Over You searched for: Author "Frumovitz, Michael" Remove constraint Author: "Frumovitz, Michael" Database Unpaywall Remove constraint Database: Unpaywall
327 results on '"Frumovitz, Michael"'

Search Results

3. Contributors

6. Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors

8. List of contributors

11. Molecular image–guided surgery in gynaecological cancer: where do we stand?

12. YAP1 status defines two intrinsic subtypes of LCNEC with distinct molecular features and therapeutic vulnerabilities

16. Comparing long-term sexual dysfunction across different uterine cancer treatment modalities

17. #657 Global survey on training in sentinel lymph node mapping for endometrial and cervical cancer

20. Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms

21. Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers

22. Abstract CT218: A phase II trial of niraparib plus dostarlimab in relapsed small cell lung cancer and other high-grade neuroendocrine carcinomas

23. Extrauterine Mesonephric-like Carcinoma

25. Abstract 4525: YAP1 in relapsed pulmonary high-grade neuroendocrine carcinomas (NEC) is associated with CDKN2A loss, intact RB1, EMT and therapeutic vulnerability to MEK1 and CDK4/6 inhibition

26. Table S6 from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer

27. Table S6 from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer

28. Table S1, Table S2, Table S3, Table S5 from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer

29. Table S4 from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer

30. Figure S1, S2, S3, S4 and S5 from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer

31. Figure S1, S2, S3, S4 and S5 from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer

32. Table S4 from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer

33. Table S1, Table S2, Table S3, Table S5 from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer

34. Data from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer

35. Data from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer

36. Figure S1 from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma

37. Figure_S6 from Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer

38. Supplemental Table 2. Distribution of primary vulvar melanomas with tumor thickness > 4.00 mm reported in literature. from Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases

39. Figure S2 from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma

40. Figure S6 from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma

41. Figure S4 from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma

42. Figure S5 from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma

43. Figure S4 from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma

44. Figure S2 from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma

45. Figure S5 from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma

46. Figure S3 from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma

47. Supplementary Tables from Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer

48. Supplemental Figure Legend from Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases

49. Supplementary Table 1. Associations between clinical and histopathologic parameters are metastasis (Fisher's exact tests). from Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases

50. Figure S6 from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma

Catalog

Books, media, physical & digital resources